<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02365714</url>
  </required_header>
  <id_info>
    <org_study_id>CRC012015-02</org_study_id>
    <nct_id>NCT02365714</nct_id>
  </id_info>
  <brief_title>CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)</brief_title>
  <acronym>CK-SAPBI</acronym>
  <official_title>A Pilot Study of Stereotactic Accelerated Partial Breast Irradiation (SAPBI) for Post-Menopausal Women (&gt;50 y/o) With Ductal Carcinoma in Situ (DCIS) or Early Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will prospectively evaluate the technical feasibility, acute toxicity, late
      effects and oncologic outcomes of CyberKnife Stereotactic Accelerated Partial Breast
      Irradiation (CK-SAPBI) in early stage breast cancer. It will evaluate quality of life (QOL)
      issues as they relate to treatment-related side effects and cosmetic results.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will determine the feasibility, acute and late toxicity as well as oncologic
      outcomes following CK-SAPBI.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual
  </why_stopped>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Endpoint for This Study is the Percentage of Enrolled Subjects in Whom CyberKnife SAPBI PBI is Technically Feasible to Deliver and Complete Treatment</measure>
    <time_frame>Enrollment to 24 months</time_frame>
    <description>Only one of two patients were able to undergo CyberKnife SAPBI. We are measuring the percentage of enrolled subjects in whom CyberKnife SAPBI PBI is technically feasible to deliver and complete treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>2 years</time_frame>
    <description>How many patients were able to undergo CK SAPBI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ipsilateral Breast Recurrence</measure>
    <time_frame>1 month post radiation treatment through 5 years post treatment</time_frame>
    <description>No patients have recurred to date.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Breast Cancer</condition>
  <condition>DCIS</condition>
  <condition>Invasive Ductal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment-Radiation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>CyberKnife (CK) Stereotactic Accelerated Partial Breast Irradiation. Adjuvant radiation therapy delivered to the region around the lumpectomy cavity. Patients will receive 30 Gy in 5 fractions over 5-14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CK Stereotactic Accelerated Partial Breast Irradiation</intervention_name>
    <description>Adjuvant radiation therapy will be delivered to the region of the lumpectomy cavity once daily for 5 treatments over 5-10 days.</description>
    <arm_group_label>Treatment-Radiation</arm_group_label>
    <other_name>CyberKnife, SAPBI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  -Newly diagnosed Stage 0 or I breast cancer.

          -  On histological examination, the tumor must be DCIS or invasive non-lobular carcinoma
             of the breast

          -  Surgical treatment of the breast must have been wide excision, lumpectomy or partial
             mastectomy

          -  Age 50 years or greater

          -  ER positive: (≥1% of breast tumor cells express ER in their nuclei)

          -  PR (progesterone receptor) positive: (≥ 1% of breast tumor cells express PR in their
             nuclei)

          -  Her2 negative (IHC 0-1+; for IHC 2+, FISH (fluorescence in situ hybridization) must be
             non-amplified)

          -  Subjects with invasive tumors should undergo axillary sentinel lymph node evaluation
             or axillary lymph node dissection.

          -  Negative inked surgical margins of excision or re-excision, clear of invasive tumor
             (no cells on ink) and DCIS by at least 1 mm

          -  Negative post-excision or post-reexcision mammography if cancer presented with
             malignancy-associated microcalcifications with no remaining suspicious calcifications
             in the breast before radiotherapy. Alternatively, a specimen radiograph can be
             obtained showing all the suspicious calcifications.

          -  No involved axillary lymph nodes, N0(i+) allowed

          -  Enrollment and the plan to initiate of CyberKnife therapy within 12 weeks of the last
             breast cancer surgery.

          -  Target lumpectomy cavity/whole breast reference volume must be &lt;30% based on treatment
             planning CT

          -  Signed study-specific informed consent form

        Exclusion Criteria:

          -  -Patients with invasive lobular carcinoma or nonepithelial breast malignancies such as
             sarcoma or lymphoma.

          -  Patients with tumors greater than 2 cm

          -  Patients with surgical margins which cannot be microscopically assessed or not cleared
             by at least 2mm at pathological evaluation.

          -  Patients with multicentric carcinoma or with other clinically or radiographically
             suspicious areas in the ipsilateral breast unless confirmed to be negative for
             malignancy by biopsy. Breast MRI will be recommended to exclude multicentric disease
             and additional suspicious areas will require biopsy to exclude malignancy.

          -  Patient with lymphovascular space invasion (LVSI).

          -  Patients with involved axillary nodes.

          -  Patients with collagen vascular diseases.

          -  Patient with known deleterious BRCA1/2 mutations or known mutations in other high
             penetrance genes (TP53, STK11, PTEN-phosphatase and tensin homolog, CDH1)

          -  Patients with prior ipsilateral breast irradiation.

          -  Patients with prior ipsilateral thoracic irradiation.

          -  Patients with Paget's disease of the nipple.

          -  Patients with diffuse suspicious microcalcifications.

          -  Patients with suspicious microcalcifications remaining on the post-excision mammogram.

          -  Patients receiving (neo)adjuvant systemic therapy other than hormonal therapy

          -  Patients with oncoplastic reconstruction and absence of surgical clips
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonali Rudra, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2015</study_first_submitted>
  <study_first_submitted_qc>February 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <results_first_submitted>March 16, 2018</results_first_submitted>
  <results_first_submitted_qc>March 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2018</results_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CyberKnife Arm</title>
          <description>This is a single arm study for patients who are eligible for partial breast irradiation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>2 patients were enrolled. Age=55 and 63 at treatment. Race=African American in both.</population>
      <group_list>
        <group group_id="B1">
          <title>CyberKnife Arm</title>
          <description>Two patients were enrolled for CyberKnife. In one patient, the fiducials were unable to be tracked, so she received external beam partial breast irradiation.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="55" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Endpoint for This Study is the Percentage of Enrolled Subjects in Whom CyberKnife SAPBI PBI is Technically Feasible to Deliver and Complete Treatment</title>
        <description>Only one of two patients were able to undergo CyberKnife SAPBI. We are measuring the percentage of enrolled subjects in whom CyberKnife SAPBI PBI is technically feasible to deliver and complete treatment</description>
        <time_frame>Enrollment to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CyberKnife Arm</title>
            <description>This is a single arm study for patients who are eligible for partial breast irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Endpoint for This Study is the Percentage of Enrolled Subjects in Whom CyberKnife SAPBI PBI is Technically Feasible to Deliver and Complete Treatment</title>
          <description>Only one of two patients were able to undergo CyberKnife SAPBI. We are measuring the percentage of enrolled subjects in whom CyberKnife SAPBI PBI is technically feasible to deliver and complete treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Feasibility</title>
        <description>How many patients were able to undergo CK SAPBI</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CyberKnife Arm</title>
            <description>This is a single arm study for patients who are eligible for partial breast irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility</title>
          <description>How many patients were able to undergo CK SAPBI</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ipsilateral Breast Recurrence</title>
        <description>No patients have recurred to date.</description>
        <time_frame>1 month post radiation treatment through 5 years post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CyberKnife Arm</title>
            <description>This is a single arm study for patients who are eligible for partial breast irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Ipsilateral Breast Recurrence</title>
          <description>No patients have recurred to date.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment-Radiation</title>
          <description>CyberKnife (CK) Stereotactic Accelerated Partial Breast Irradiation. Adjuvant radiation therapy delivered to the region around the lumpectomy cavity. Patients will receive 30 Gy in 5 fractions over 5-14 days.
CK Stereotactic Accelerated Partial Breast Irradiation: Adjuvant radiation therapy will be delivered to the region of the lumpectomy cavity once daily for 5 treatments over 5-10 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RT dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sonali Rudra, M.D.</name_or_title>
      <organization>Medstar Georgetown University Hospital</organization>
      <phone>202-444-3320</phone>
      <email>sonali.rudra@gunet.georgetown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

